AAPL   314.93 (-0.57%)
FB   224.65 (-3.25%)
GOOGL   1,407.27 (-0.99%)
AMZN   2,375.81 (-1.90%)
NVDA   330.51 (-5.22%)
CGC   19.37 (-3.20%)
MU   44.45 (-2.95%)
GE   7.32 (+7.65%)
AMD   50.25 (-5.33%)
T   31.89 (+3.47%)
ACB   15.36 (-1.60%)
F   6.01 (+2.91%)
GILD   73.58 (+0.55%)
DIS   120.90 (-0.04%)
BAC   25.47 (+4.90%)
BA   145.83 (+0.75%)
AAPL   314.93 (-0.57%)
FB   224.65 (-3.25%)
GOOGL   1,407.27 (-0.99%)
AMZN   2,375.81 (-1.90%)
NVDA   330.51 (-5.22%)
CGC   19.37 (-3.20%)
MU   44.45 (-2.95%)
GE   7.32 (+7.65%)
AMD   50.25 (-5.33%)
T   31.89 (+3.47%)
ACB   15.36 (-1.60%)
F   6.01 (+2.91%)
GILD   73.58 (+0.55%)
DIS   120.90 (-0.04%)
BAC   25.47 (+4.90%)
BA   145.83 (+0.75%)
AAPL   314.93 (-0.57%)
FB   224.65 (-3.25%)
GOOGL   1,407.27 (-0.99%)
AMZN   2,375.81 (-1.90%)
NVDA   330.51 (-5.22%)
CGC   19.37 (-3.20%)
MU   44.45 (-2.95%)
GE   7.32 (+7.65%)
AMD   50.25 (-5.33%)
T   31.89 (+3.47%)
ACB   15.36 (-1.60%)
F   6.01 (+2.91%)
GILD   73.58 (+0.55%)
DIS   120.90 (-0.04%)
BAC   25.47 (+4.90%)
BA   145.83 (+0.75%)
AAPL   314.93 (-0.57%)
FB   224.65 (-3.25%)
GOOGL   1,407.27 (-0.99%)
AMZN   2,375.81 (-1.90%)
NVDA   330.51 (-5.22%)
CGC   19.37 (-3.20%)
MU   44.45 (-2.95%)
GE   7.32 (+7.65%)
AMD   50.25 (-5.33%)
T   31.89 (+3.47%)
ACB   15.36 (-1.60%)
F   6.01 (+2.91%)
GILD   73.58 (+0.55%)
DIS   120.90 (-0.04%)
BAC   25.47 (+4.90%)
BA   145.83 (+0.75%)
Log in

NASDAQ:ARWRArrowhead Pharmaceuticals Earnings Date, Estimates & History

$32.57
-1.14 (-3.38 %)
(As of 05/27/2020 11:56 AM ET)
Add
Compare
Today's Range
$31.57
Now: $32.57
$34.22
50-Day Range
$26.12
MA: $35.22
$39.47
52-Week Range
$19.51
Now: $32.57
$73.72
Volume71,216 shs
Average Volume1.11 million shs
Market Capitalization$3.31 billion
P/E Ratio361.93
Dividend YieldN/A
Beta1.82

Earnings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings Information

Arrowhead Pharmaceuticals last posted its quarterly earnings data on May 7th, 2020. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.09. The business earned $23.53 million during the quarter, compared to analyst estimates of $21.90 million. Arrowhead Pharmaceuticals has generated $0.69 earnings per share over the last year and currently has a price-to-earnings ratio of 361.9. Arrowhead Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 3rd, 2020 based off prior year's report dates.

Arrowhead Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings Estimates

2020 EPS Consensus Estimate: ($0.09)
2021 EPS Consensus Estimate: ($1.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20204($0.09)$0.35$0.09
Q2 20208($0.15)$0.01($0.10)
Q3 20208($0.35)$0.57($0.08)
Q4 20208($0.22)$0.79($0.01)
Q1 20212($0.25)($0.24)($0.25)
Q2 20212($0.27)($0.26)($0.27)
Q3 20211($0.28)($0.28)($0.28)
Q4 20212($0.31)($0.30)($0.31)

Arrowhead Pharmaceuticals (NASDAQ ARWR) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
8/3/2020
(Estimated)
       
5/7/20203/31/2020($0.11)($0.20)($0.20)$21.90 million$23.53 millionTranscript
2/5/202012/31/2019$0.04($0.03)($0.03)$36.63 million$29.46 millionTranscript
11/25/2019Q4$0.14$0.11$0.11$36.97 million$43.29 millionTranscript
8/5/2019Q3 2019$0.34$0.21$0.21$59.05 million$42.70 millionTranscript
5/8/20193/31/2019$0.22$0.24$0.24$45.78 million$48.15 millionTranscript
2/7/201912/31/2018$0.76$0.13$0.13$90.88 million$34.66 millionN/A
12/11/2018Q4 2018($0.17)($0.12)($0.12)$3.73 million$11.26 millionTranscript
8/7/2018Q3 2018($0.19)($0.18)($0.18)$0.62 million$0.73 millionN/A
5/8/2018Q2 2018($0.19)($0.18)($0.18)$4.04 million$0.65 millionN/A
2/9/2018Q1 2018($0.14)($0.18)($0.18)$8.71 million$3.51 millionTranscript
12/12/2017Q4 2017($0.12)($0.14)($0.14)$7.32 million$8.71 millionN/A
8/3/2017Q3 2017($0.13)($0.07)($0.07)$5.29 million$9.34 millionListen
5/3/2017Q2 2017($0.1230)($0.08)($0.08)$4.19 million$8.99 millionListen
2/6/2017Q117($0.20)($0.17)($0.17)$13.24 million$4.37 millionListen
12/14/2016Q4 2016($0.33)($0.31)($0.28)$0.04 million$0.03 millionN/A
8/9/2016Q316($0.37)($0.32)($0.32)$0.05 million$39.58 millionN/A
5/10/2016Q216($0.37)($0.35)($0.35)$0.26 million$0.04 millionListen
2/9/2016Q1($0.41)($0.32)($0.32)$0.29 million$0.04 millionN/A
12/14/2015Q415($0.39)($0.42)($0.42)$0.14 million$0.04 millionListen
8/4/2015Q315($0.38)($0.27)($0.27)$0.11 million$0.12 millionN/A
5/11/2015Q214($0.35)($0.33)($0.15)$110.00 million$43.75 millionListen
2/9/2015Q114($0.32)($0.41)($0.41)$0.24 million$0.17 millionN/A
11/25/2014Q413($0.25)($0.33)($0.24)$0.04 million$0.04 millionTranscript
8/12/2014Q313($0.22)($0.22)($0.22)$0.04 million$0.04 millionTranscript
5/6/2014Q2 2014($0.18)($0.31)($0.31)$0.05 million$0.04 millionN/A
2/4/2014Q1 2014($0.18)($0.28)($0.28)$0.05 million$0.04 millionN/A
12/18/2013Q4($0.23)($0.43)Listen
8/7/2013Q3 2013($0.22)($0.23)($0.23)$0.50 million$0.04 millionN/A
5/9/2013Q2 2013($0.41)($0.41)$0.04 millionListen
2/13/2013Q1 2013($0.33)Transcript
12/20/2012Q4 2012($0.43)N/A
8/13/2012Q3 2012($0.71)($0.71)N/A
5/8/2012Q2 2012($0.44)($0.38)N/A
2/9/2012Q1 2012($0.25)($0.25)N/A
12/20/2011Q4 2011($0.39)($0.39)N/A
8/8/2011Q3 2011($0.20)($0.26)($0.27)N/A
5/12/2011Q2 2011($0.20)($0.18)($0.73)N/A
2/10/2011Q1 2011($0.20)($0.20)N/A
12/22/2010Q4 2010($0.30)($0.28)($0.28)N/A
8/12/2010Q3 2010($0.50)($0.06)($0.06)N/A
5/13/2010Q2 2010($0.40)($0.33)($0.33)N/A
2/11/2010Q1 2010($0.30)($0.30)N/A
12/22/2009Q4 2009($0.60)($0.60)N/A
8/10/2009Q3 2009($0.60)($0.60)N/A
5/15/2009Q2 2009($1.20)($1.20)N/A
2/9/2009Q1 2009($1.90)($1.90)N/A
12/15/2008Q4 2008($2.14)($2.14)N/A
8/11/2008Q3 2008($1.90)($1.90)N/A
2/11/2008Q1 2008($1.40)($1.40)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.